Parkinson Disease Therapy Market Analysis and Trends – Industry Forecast 2023

Posted on Oct 25 2019 10:22 AM

"The study contains thoughtful insights, facts, Parkinson Disease Therapy Market historical data, and statistically supported and industry-validated market data. This Parkinson Disease Therapy Market report also explores Business models, Key strategies and Growth opportunities in upcoming years."

Parkinson's disease (PD) is a progressive nervous system disorder that gradually affects movement. Symptoms starts with mild tremor in just one hand and then spreads causing stiffness or slowing of movement. The other common symptoms restriction in facial muscle movement, speech disorder, movement limitations of limbs, muscle tightness, impaired posture and balance etc. It challenges the quality of life and increases the burden of care, particularly in the advanced disease stages. PD-associated dementia and PD-associated psychosis are both cognitive and behavioural complications of PD that are highly prevalent and associated with a large disease burden. There is a growing demand of effective pharmacotherapies for PD, PD-associated dementia, and PD-associated psychosis. Even though present therapies can provide temporary relief to the patients, there are no commercially available therapies that is capable of preventing or reducing the degree of its intensity. This report is prepared to understand the innovation within the pipeline for Parkinson Disease Therapy Market and its behavioral complications.

Top Companies mentioned in this report:

  • AbbVie and Voyager Therapeutics Enter into Co-development Agreement
  • Axovant Sciences Enters into Licensing Agreement with Oxford Biomedica
  • Pfizer Enters into Licensing Agreement with Arvinas
  • And more…

Download FREE PDF sample of this Report @

Scope of the Report:-

The report helps to determine the fact that the Parkinson Disease pipeline market is large, with 456 programs being active for development. Further, there are other products in development process for the behavioral complications of PD among them 16 products that is being developed for PD-associated dementia and 6 products for PD-associated psychosis. It also helps to determine the proportion of these products across PD and PD behavioral complications as first in class. Further is derives that first-in-class innovation vary by development stage and molecular target class.

The innovative molecular target groups identified in the pipeline comprises immunomodulators, neuroprotectants, protein misfolding and aggregation. The report also helps to assess the molecular target classes that majorly represented in the overall and first-in-class pipelines for PD and PD behavioral complications

This report is prepared by studying around 351 key market players active across PD and PD behavioral complications. It provides a drill down analysis about the companies that have the most first-in-class assets in development, the companies that are highly active for licensing and co-development deals for first-in-class innovation

What are the prime reasons to buy this report?

The PD pipeline and behavioural complication market research report helps to understand the current disease scenario with a broad and detailed analysis of aetiology, pathophysiology, disease classification and staging systems, epidemiology, and promoted therapies for PD. The overviews of PD-associated dementia and PD-associated psychosis are also provided.

The report helps to analyze the pipelines for PD, PD-associated dementia, and PD-associated psychosis, and derive a strategic approach by stage of development, molecule type, and molecular target.

Using registered matrix assessments, the therapeutic potential for first-in-class molecular targets are determined through this report and ranked according to clinical importance. However, for PDl-associated psychosis, the matrix assessment cannot be provided due to a lack of first-in-class innovation. On the other hand, first-in-class targets for PD and PD-associated dementia have been studied in detail.

The report also helps to analyze business plans of the major market drivers through case studies of major transactions for PD first-in-class products, and recognize growth factors and scope of business by identifying the unutilized first-in-class pipeline products.

Direct Purchase to Get FLAT 15% Discount on this Report @

Table of Contents in this Parkinson Disease Therapy Market Report:-
1.1 List of Tables
1.2 List of Figures
2 Parkinson’s Disease and Behavioral Complications: Executive Summary
2.1 High Unmet Need Remains for Disease-Modifying Pharmacotherapies
2.2 Large and Innovative Parkinson’s Disease Pipeline Indicates Shift Towards Disease-Modifying Approaches
2.3 Novel Gene Therapies Attract High Levels of Investment in Parkinson’s Disease
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
4.3 Sustained Innovation in Parkinson’s Disease
4.4 Epidemiology for Parkinson’s Disease
4.5 Overview for Marketed Products
4.6 Overview for Behavioral Complications in Parkinson’s Disease
4.6.1 Overview of Parkinson’s Disease-Associated Dementia
4.6.2 Overview of Parkinson’s Disease-Associated Psychosis
5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs Between the Parkinson’s Disease Market and Pipeline by Therapeutic Target Family
5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs
5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Targets Within the Pipeline
6 First-in-Class Molecular Target Evaluation
6.1 Overview
6.2 Pipeline Programs Targeting Alpha Synuclein for Parkinson’s Disease and Parkinson’s Disease-Associated Dementia
6.3 Pipeline Programs Targeting Microtubule-Associated Protein Tau for Parkinson’s Disease
6.4 Pipeline Programs Targeting Glial Cell Line-Derived Neurotrophic Factor for Parkinson’s Disease
6.5 Pipeline Programs Targeting Metabotropic Glutamate Receptor 4 and Metabotropic Glutamate Receptor 5 for Parkinson’s Disease
6.6 Pipeline Programs Targeting GDNF Family Receptor Alpha 1 and GDNF Family Receptor Alpha 2 for Parkinson’s Disease
6.7 Pipeline Programs Targeting Pituitary Adenylate Cyclase-Activating Polypeptide Type I Receptor for Parkinson’s Disease
6.8 Pipeline Programs Targeting Caveolin-1 for Parkinson’s Disease-Associated Dementia
6.9 Pipeline Programs Targeting Mitogen-Activated Protein Kinase 14 for Parkinson’s Disease-Associated Dementia
7 Key Players and Deals
7.1 Overview
7.1.1 AbbVie and Voyager Therapeutics Enter into Co-development Agreement
7.1.2 Axovant Sciences Enters into Licensing Agreement with Oxford Biomedica
7.1.3 Pfizer Enters into Licensing Agreement with Arvinas
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
8.4 About the Authors
8.4.1 Analyst
8.4.2 Therapy Area Director
8.4.3 Global Director of Therapy Analysis and Epidemiology
8.4.4 Global Head and EVP of Healthcare Operations and Strategy

and more..